(Adds CEO comments on M&A) By Steven Scheer TEL AVIV, Feb 20 (Reuters) – Teva Pharmaceutical Industries will remain a single company for generic and branded drugs, and expects to see significant interest in its active pharmaceutical ingredients business that it plans to divest, its head said on Tuesday. There has been speculation that Israel-based […]
(Adds share movement in paragraph 3, background throughout) Jan 31 (Reuters) – Teva Pharmaceutical Industries will divest its active pharmaceutical ingredient (API) unit to focus on its core business, the world’s largest generic drugs maker said on Wednesday. The API unit, which brought in revenue of $1.05 billion in 2022, makes pharmaceutical ingredients that are […]